Medication adjustment of afatinib and combination therapy with sitagliptin for alleviating afatinib-induced diarrhea in rats

Afatinib, as the first-line treatment for non-small cell lung cancer (NSCLC), causes severe gastrointestinal adverse reactions that greatly affect patients' quality of life and even potentially result in treatment discontinuation. Multiple dose adjustments and concomitant use of anti-diarrheal...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Li, Hu, Anna, Wang, Yan, Yang, Yuxin, Liu, Yalan, Xu, Lian, Wang, Lei, Cheng, Zeneng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423691/
https://www.ncbi.nlm.nih.gov/pubmed/37567055
http://dx.doi.org/10.1016/j.neo.2023.100922

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423691/
https://www.ncbi.nlm.nih.gov/pubmed/37567055
http://dx.doi.org/10.1016/j.neo.2023.100922

Ejemplares similares